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Summary
Background COVID-19 vaccine supply shortages are causing concerns about compromised immunity in some 
countries as the interval between the first and second dose becomes longer. Conversely, countries with no supply 
constraints are considering administering a third dose. We assessed the persistence of immunogenicity after a 
single dose of ChAdOx1 nCoV-19 (AZD1222), immunity after an extended interval (44–45 weeks) between the first 
and second dose, and response to a third dose as a booster given 28–38 weeks after the second dose.
Methods In this substudy, volunteers aged 18–55 years who were enrolled in the phase 1/2 (COV001) controlled trial 
in the UK and had received either a single dose or two doses of 5 × 10¹⁰ viral particles were invited back for 
vaccination. Here we report the reactogenicity and immunogenicity of a delayed second dose (44–45 weeks after 
first dose) or a third dose of the vaccine (28–38 weeks after second dose). Data from volunteers aged 18–55 years 
who were enrolled in either the phase 1/2 (COV001) or phase 2/3 (COV002), single-blinded, randomised controlled 
trials of ChAdOx1 nCoV-19 and who had previously received a single dose or two doses of 5 × 10¹⁰ viral particles are 
used for comparison purposes. COV001 is registered with ClinicalTrials.gov, NCT04324606, and ISRCTN, 15281137, 
and COV002 is registered with ClinicalTrials.gov, NCT04400838, and ISRCTN, 15281137, and both are continuing 
but not recruiting.
Findings Between March 11 and 21, 2021, 90 participants were enrolled in the third-dose boost substudy, of whom 
80 (89%) were assessable for reactogenicity, 75 (83%) were assessable for evaluation of antibodies, and 15 (17%) were 
assessable for T-cells responses. The two-dose cohort comprised 321 participants who had reactogenicity data (with 
prime-boost interval of 8–12 weeks: 267 [83%] of 321; 15–25 weeks: 24 [7%]; or 44–45 weeks: 30 [9%]) and 261 who 
had immunogenicity data (interval of 8–12 weeks: 115 [44%] of 261; 15–25 weeks: 116 [44%]; and 44–45 weeks: 
30 [11%]). 480 participants from the single-dose cohort were assessable for immunogenicity up to 44–45 weeks after 
vaccination. Antibody titres after a single dose measured approximately 320 days after vaccination remained higher 
than the titres measured at baseline (geometric mean titre of 66·00 ELISA units [EUs; 95% CI 47·83–91·08] 
vs 1·75 EUs [1·60–1·93]). 32 participants received a late second dose of vaccine 44–45 weeks after the first dose, of 
whom 30 were included in immunogenicity and reactogenicity analyses. Antibody titres were higher 28 days after 
vaccination in those with a longer interval between first and second dose than for those with a short interval 
(median total IgG titre: 923 EUs [IQR 525–1764] with an 8–12 week interval; 1860 EUs [917–4934] with a 15–25 week 
interval; and 3738 EUs [1824–6625] with a 44–45 week interval). Among participants who received a third dose of 
vaccine, antibody titres (measured in 73 [81%] participants for whom samples were available) were significantly 
higher 28 days after a third dose (median total IgG titre: 3746 EUs [IQR 2047–6420]) than 28 days after a second 
dose (median 1792 EUs [IQR 899–4634]; Wilcoxon signed rank test p=0·0043). T-cell responses were also boosted 
after a third dose (median response increased from 200 spot forming units [SFUs] per million peripheral blood 
mononuclear cells [PBMCs; IQR 127–389] immediately before the third dose to 399 SFUs per milion PBMCs 
[314–662] by day 28 after the third dose; Wilcoxon signed rank test p=0·012). Reactogenicity after a late second dose 
or a third dose was lower than reactogenicity after a first dose.
Interpretation An extended interval before the second dose of ChAdOx1 nCoV-19 leads to increased antibody titres. 
A third dose of ChAdOx1 nCoV-19 induces antibodies to a level that correlates with high efficacy after second dose and 
boosts T-cell responses.
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The COVID-19 pandemic continues to put a substantial 
burden on health-care systems and a massive global 
effort is underway to protect populations through 
vaccination. COVID-19 vaccine supply shortages in 
many countries are causing concern about com-
promised immunity as the interval between the first 
and second dose extends beyond 12 weeks.1 WHO 
recommends that the second dose of the ChAdOx1 
nCoV-19 vaccine is given 8–12 weeks after the first dose 
because the clinical trial data provide support for good 
levels of protection with this interval;2,3 however, many 
countries cannot obtain sufficient supplies to allow 
second doses to be administered by 12 weeks. These 
supply shortages are leading to longer intervals and 
uncertainty among policy makers about whether 
protection against COVID-192,3 will be maintained 
because no data exist on the efficacy of the immunisation 
schedules with intervals between the first and second 
dose that extend beyond this limit.
Conversely, some high-income countries with highly 
vaccinated populations are considering administration of 
a third dose of a COVID-19 vaccine because of uncertainty 
about duration of immunity after the first two doses and 
the possible risk of breakthrough infection as new 
variants emerge.
ChAdOx1 nCoV-19 (AZD1222), a replication deficient 
adenoviral vectored vaccine that encodes the SARS-CoV-2 
spike protein, is one of the most widely used vaccines 
globally. More than half a billion doses have been 
distributed to more than 168 countries across six 
continents, including provision through the COVAX 
Facility. Here, we describe tolerability and immune 
response to a late second dose (44–45 weeks after the 
first dose) of ChAdOx1 nCoV-19, and after a third dose 
(28–38 weeks after the second dose). We also report 
the persistence of antibody and cellular responses at 
182 days and for antibodies up to 320 days after first 
dose of ChAdOx1 nCoV-19.
Methods
Study design and participants
In this substudy, we extended the data already collected 
as part of the UK COV001 and COV002 trials. In these 
trials, participants were randomly assigned to receive 
ChAdOx1 nCoV-19 or a meningococcal conjugate vaccine 
(MenACWY) as a control. Procedures, safety, immune 
responses, and efficacy before late vaccination and after 
Research in context
Evidence before this study
Multiple vaccines against SARS-CoV-2 have now been 
authorised for use in various countries. Most vaccines are given 
in a two-dose primary schedule, and further doses might be 
required to maintain protective immunity or control emerging 
variants. We searched PubMed for research articles published 
between database inception and June 23, 2021, using the search 
terms “SARS-CoV-2”, “vaccine”, “clinical trial”, AND (“third dose” 
OR “late boost”) with no language restrictions. We identified 
animal studies using combinations of three-dose vaccine 
delivery in prime-boost schedules. Additionally, we identified 
three clinical trials of three-dose delivery, including two in solid 
organ transplant recipients. In the first study in transplant 
recipients, antibody titres increased after the third dose of either 
BNT162b2 (Pfizer–BioNTech) or mRNA-1273 (Moderna) 
vaccines in a third of patients who had negative antibody titres 
and in all patients who had low-positive antibody titres. In the 
second study in transplant recipients, prevalence of antibody 
titres increased from 44% after a second dose to 68% after a 
third dose. In a phase 1 and 2 trial of a protein subunit vaccine 
ZF2001, the safety and immunogenicity data support the use of 
a 25 μg dose in a three-dose schedule. A number of clinical 
studies are measuring the effect of a third dose of vaccine, 
including a phase 1 study of 144 participants who received a 
homologous third dose of BNT162b2, 6 or 12 months after the 
second dose.
Added value of this study
We report immune responses to ChAdOx1 nCoV-19 following a 
second dose after an extended interval between the first and 
second dose, and after a third dose with an extended interval 
between the second and third dose. The extended interval 
between the first two doses (44–45 weeks) resulted in higher 
antibody titres after the second dose than with a shortened 
interval. A third dose given 28–38 weeks after the primary 
series increased the antibody titres to above those after a 
second dose with a shortened interval. Reactogenicity was 
lower after the second or third dose than after the first dose.
Implications of all the available evidence
Vaccine shortages have resulted in some people receiving a 
first dose of ChAdOx1 nCoV-19 without receiving the second 
dose within the recommended 4–12 week period. We report that 
increasing the interval up to 45 weeks results in increased 
antibody titres after the second dose, offering increased flexibility 
in vaccination schedules. A third dose at an extended interval 
after the second dose resulted in a further increase in antibody 
titres, mitigating concerns that antibodies raised against the 
ChAdOx1 vector would limit repeated use of the vaccine.
For more on COVAX see 
https://www.who.int/initiatives/
act-accelerator/covax
Biomedical Research Centre, Chinese Academy of Medical Sciences Innovation Fund for Medical Science, Thames 
Valley and South Midlands NIHR Clinical Research Network, AstraZeneca, and Wellcome.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
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second dose have been previously published.2,4,5 The 
trials were originally planned as single-dose vaccine 
studies, but the strong neutralising titres seen in 
COV001 induced by a second dose of vaccine4 prompted 
a protocol amendment to allow the addition of booster 
doses to most study participants across both trials. 
Most participants in both COV001 and COV002 were 
invited to receive a second dose from July, 2020, onwards. 
The timing of the second dose varied and allows for 
comparisons of immunogenicity between the recom-
mended vaccination schedule in the UK of 8–12 weeks 
and a longer interval of 15–25 weeks.3 The initial phase 1 
immunogenicity group in COV001 was retained as a 
single-dose cohort to observe the persistence of immune 
responses after a single dose.
For analysis of immunogenicity after a single dose of 
ChAdOx1 nCoV-19, we included all participants in COV001 
and COV002 who had yet to receive a second dose of 
vaccine and for whom immunogenicity data were available.
A substudy was added to the COV001 trial as a protocol 
amendment on March 1, 2021, to investigate the 
immunogenicity and tolerability of a third dose of the 
vaccine. Participants who had previously received two 
doses of ChAdOx1 nCoV-19 were recruited for this 
substudy, along with control participants, who had 
received two doses of MenACWY previously, to maintain 
blinding of reactogenicity data. All recruits received 
ChAdOx1 nCoV-19; for the control participants this was 
their first dose. For participants from this three-dose 
cohort to be eligible for inclusion in these analyses, 
they had to have an 8–16 week interval between first and 
second doses.
Some participants from the COV001 single-dose 
cohort were also offered a second dose at this time. 
The single dose cohort originally comprised a 1:1 ratio of 
ChAdOx1 nCoV-19 recipients to MenACWY controls. 
These participants were invited back in a 2:1 ratio, so 
participants who had previously received a single dose of 
ChAdOx1 nCoV-19 received their second dose, with an 
interval of 44–45 weeks, and those who had been controls 
received their first dose of ChAdOx1 nCoV-19. Participants 
were targeted for inclusion in the substudy if they had not 
previously been unmasked to treatment allocation or 
offered a vaccine as part of the UK Government COVID-19 
vaccine programme. A subset of two-dose recipients (for 
whom reactogenicity or immunogenicity data, or both, 
were available) were selected for inclusion in analyses 
for comparison with those who received two doses 
44–45 weeks apart. Participants who had a positive PCR 
test for SARS-CoV-2 were removed from the analysis if 
the infection occurred before the blood draw. Participants 
for this substudy were only enrolled at the Oxford site.
In the UK, the COV001 and COV002 studies were 
approved by the South Central Berkshire Research 
Ethics Committee (COV001 reference 20/SC/0145, on 
March 23, 2020; COV002 reference 20/SC/0179; con-
ditional approval on April 8, 2020, and full approval on 
April 19, 2020). The protocol for COV001 is provided in 
appendix 1 and the protocol for COV002 is provided in 
appendix 2.
Procedures
Participants who were included as part of this substudy 
were vaccinated with a standard dose of ChAdOx1 
nCoV-19 (5 × 10¹⁰ viral particles). For control participants 
who had previously received either one or two doses of 
MenACWY, this vaccination was their first dose of 
ChAdOx1 nCoV-19. For participants who had previously 
received ChAdOx1 nCoV-19, this vaccination was either 
their second dose (44–45 weeks after the first) or their 
third dose. These late vaccinations occurred 10 months 
(plus or minus 56 days) from enrolment. 7 days after 
vaccination participants were unmasked to treatment 
allocation, so that those who had received only one dose 
of ChAdOx1 nCoV-19 could subsequently receive a 
second dose, in line with national vaccination roll-out in 
the UK.
Participants enrolled in the substudy had blood samples 
taken on the day of vaccination, and then at 14 days and 
28 days after vaccination to allow immunogenicity assess-
ments to be made.
Binding antibody titres were measured using 
standardised single dilution total IgG ELISAs as previously 
described.5 This assay was used to measure antibody 
responses before and after vaccination to Victoria/01/2020 
SARS-CoV-2 spike protein and adapted to measure 
responses to beta (B.1.351) SARS-CoV-2 protein. ELISA 
assays to Victoria/01/2020 were performed on samples 
See Online for appendix 1
See Online for appendix 2
Figure 1: Trial profile for three-dose cohort
90 participants were enrolled and received their 
third dose of ChAdOx1 nCoV-19
80 participants assessable for reactogenicity
 
10 excluded because included in an open-label 
subgroup and interval between doses one 
and two was <28 days
 
75 assessable for antibody immunogenicity 
assessment 
5 excluded because their prime-boost interval 
was outside of the defined interval 
(8–16 weeks)
15 assessable for T-cell response 
immunogenicity assessments
60 excluded 
 56 no ELISPot data
 4 insufficient ELISpot data
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from single-dose recipients up to 1 year after vaccination, 
in two-dose recipients up to 6 months after the second 
vaccination, and in three-dose recipients up to 28 days 
after the third vaccination. ELISA assays on the beta 
SARS-CoV-2 variant were only done on samples from 
participants recruited to the substudy who received either 
a late second vaccination or a third vaccination, up to 
28 days after the late vaccination. Meso Scale Discovery 
multi plex immunoassay was used to assess antibody 
titres against spike proteins from different variants 
(Victoria/01/2020, D614G, alpha [B.1.17], beta, and 
gamma [P.1]). V-PLEX SARS-CoV-2 Panel 6 (IgG) kits were 
used following manufacturer’s instructions (Meso Scale 
Discovery, K15433U; full details are in appendix 3 [p 1]). 
Meso Scale Discovery assays were done on samples from 
participants recruited to the substudy who received a late 
second dose of vaccine (44–45 weeks after the first dose. 
Ex-vivo IFN-γ ELISpot assays were done as previously 
described5 to assess T-cell responses to Victoria/01/2020 
SARS-CoV-2 spike over lapping peptide pools before and 
after vac cination. Isolated peripheral blood mononuclear 
cells (PBMCs) were stimulated overnight with peptides 
spanning the SARS-CoV-2 spike insert. ELISpot assays 
were done on samples from participants in the single 
dose cohort up to 182 days after vaccination. ELISpot 
assays were also done in some participants (due to 
laboratory capacity) recruited to the substudy who 
received a third dose, up to 28 days after third dose. Focus 
reduction neutralisation assays were done as described 
previously6 to measure neutralising antibody titres 
against alpha, beta, and delta (B.1.617.2) SARS-CoV-2 viral 
variants. Neu tralisation assays were done in a randomly 
selected subset of participants (due to laboratory capacity) 
who received a third dose of vaccine. Timepoints assessed 
were 28 days after second vaccination and 28 days after 
third vaccination.
For all immunogenicity assessments, data were 
excluded upon earliest occurrence of a positive PCR test 
result or external COVID-19 vaccination. For single dose 
immunogenicity assessments, data were excluded from 
after receipt of second dose. For the three-dose cohort, 
data were included only for those who had an interval of 
8–16 weeks between first and second doses.
Participants were asked to complete a diary card for 
7 days after each vaccination to record solicited local 
(induration, itch, pain, redness, swelling, tenderness, and 
warmth at the injection site) and systemic (chills, fatigue, 
fever of ≥38°C, feverish [self-reported feeling of feverish-
ness, whereas fever is an objective fever measurement], 
headache, joint pain, malaise, muscle ache, and nausea) 
adverse reactions. Participants reported the severity of their 
adverse reactions as mild, moderate, severe, or life threaten-
ing as per definitions provided (appendix 1 pp 92–94).
Figure 2: Solicited adverse reactions up to 7 days after ChAdOx1 nCoV-19 
vaccination by interval between first and second doses (A) and after the first, 
second, and third dose for participants who received a third dose of vaccine (B)
Figure shows maximum severity of respective solicited adverse event recorded 
for each participant during days 0–7 after vaccination. In panel A, reactogenicity 
data after the second dose are shown for 263 participants for fever (≥38°C) and 
267 participants for all other symptoms for the 8–12 week interval, for 
23 participants for fever (≥38°C) and 24 participants for all other symptoms for 
the 15–25 week interval, and 28 participants for fever (≥38°C) and 30 participants 
for all other symptoms for the 44–45 week interval. In panel B, reactogenicity 
data are from after each dose recorded by participants who received a third dose 
of vaccine, with data available for 80 participants for all symptoms after dose 1; 
15 participants for all symptoms after dose 2; and 77 participants for fever and 
80 participants for all symptoms after dose 3. Participants included in panel B 
received their third dose 20–38 weeks after the second dose (median of 30 weeks 
[IQR 30–30]).
See Online for appendix 3
Figure 3: Antibody (A) and T-cell (B) persistence after one dose of ChAdOx1 nCoV-19 vaccine
Datapoints represent individual participants and the solid line represents estimates from a linear regression model, 
with shaded areas showing the 95% CI. Antibody levels to SARS-CoV-2 Victoria/01/2020 spike measured by total 
IgG ELISA over 1 year after a single dose. Data are from 480 participants across COV001 and COV002 who received 
a standard dose of ChAdOx1 nCoV-19. Vaccine-induced T-cell responses against the SARS-CoV-2 spike insert were 
monitored up to day 182 in a cohort of 44 participants who received a single dose of ChAdOx1 nCoV-19. 
For participants who were excluded from these analyses due to positive PCR test result, second dose on trial, 
or external COVID-19 vaccination, no ELISA results or ELISpot results beyond the date of censoring were used. 
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Statistical analysis
We present summary statistics for individuals 
vaccinated with one, two, or three doses of ChAdOx1 
nCoV-19 as median (IQR) or geometric mean titre 
(GMT) with 95% CIs. We do not include data from 
control participants (who had previously received one 
or two doses of MenACWY); they received ChAdOx1 
nCoV-19 on recruitment to the substudy. For the 
purposes of ensuring trial personnel were masked to 
treatment assignment, data for both vaccinnees and 
controls were collected. Unmasking information was 
only available to those performing the final data 
analyses. Upon unmasking of participants and study 
personnel, control participants were excluded.
We used the Wilcoxon rank sum and Kruskal-Wallis 
tests for comparisons between independent groups and 
we used the Wilcoxon sign rank test to compare paired 
data. Geometric mean ratios (GMRs) with 95% CIs were 
produced when comparing groups. When appropriate, 
adjusted GMTs and GMRs were also presented to adjust 
for the effect of age. We did not do a sample size 
calculation for the immuno genicity subgroups in this 
analysis because of logistical considerations, including 
laboratory capacity. Sample size calculations for COV001 
and COV002 were based on the primary efficacy outcome, 
which have been previously reported.
The reactogenicity cohorts included masked 
participants who received at least two standard doses of 
ChAdOx1 nCoV-19 in the two-dose cohort or three 
standard doses of ChAdOx1 nCoV-19 in the three-dose 
cohort, and had completed at least one entry in their 
adverse event diary after each dose. For consistency 
between cohorts, participants were excluded from the 
two-dose reacto genicity cohort if the interval between 
first and second dose was outside of the intervals defined 
in the two-dose immunogenicity cohort. All analyses of 
COV002 participants were restricted to those aged 
18–55 years, to align with the inclusion criteria of the 
COV001 study, which only enrolled participants in this 
age range.
Our analysis of the decay of antibodies and T-cell 
responses over time after a single dose included all 
available data from timepoints up until the booster 
dose was administered (ie, day 28 and the day of the 
second dose, which varied across all participants). We 
modelled data using an unadjusted restricted-maximum 
likelihood-based mixed-effects regression approach 
(SAS proc mixed) with participant-level random inter-
cepts fitted to log-transformed antibody values. We 
used the variance components covariance structure. We 
estimated GMRs and GMTs from the linear combination 
of model parameters. We chose the linear models after 
comparison with quadratic models and generalised 
additive (smoothed) models (GAM). The quadratic term 
was non-significant in the linear models and the GAM 
results were similar and did not substantially improve 
the model fits (compared using Akaike information 
criterion [known as AIC] statistics) from the linear 
models; therefore, the linear models were retained.
We did all statistical analyses using R (version 4.0.2 or 
later) and SAS (version 9.2). p values of less than 0·05 
were considered to be significant and we made no 
adjustments for multiple comparisons. COV001 is 
registered with ClinicalTrials.gov, NCT04324606, and 
ISRCTN, 15281137, and COV002 is registered with 
ClinicalTrials.gov, NCT04400838, and ISRCTN, 15281137, 
and both are no longer recruiting.
Role of the funding source
AstraZeneca reviewed the manuscript before submission, 
but the academic authors retained editorial control. 
All other funders of the study had no role in the study 
design, data collection, data analysis, data interpretation, 
or writing of the report.
Results
Between March 11 and 21, 2021, 90 participants were 
enrolled into the COV001 third-dose boost substudy and 
vaccinated with ChAdOx1 nCoV-19. Ten participants 
from this substudy were excluded from analyses 
because they were enrolled from an open-label subgroup 
and the interval between their first and second doses 
was shorter than 28 days. The remaining 80 participants 
who were assessable for reactogenicity received their 
third dose of vaccine 20–38 weeks after their second 
dose (median 30 weeks [IQR 30–30]). A further five 
participants were excluded from all immunogenicity 
assessments because their prime-boost interval was 
outside the defined range of 8–16 weeks. For 
Figure 4: Antibody response by interval between first and second vaccination
Datapoints are medians for each group, with error bars showing IQRs. Antibody levels to SARS-CoV-2 
Victoria/01/2020 spike measured by total IgG ELISA. Data are shown for 115 participants for the 8–12 week 
interval; 116 participants for the 15–25 week interval, and 30 participants for the 44–45 week interval. Unadjusted 
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immunogenicity analysis of T-cell responses, another 
60 participants were excluded because they did not have 
or had insufficient ELISpot data, leaving an analysable 
cohort of 15 participants (figure 1). To maintain blinding 
at the time of vaccination, 40 control participants (who 
had previously received two doses of MenACWY) were 
also recruited and vaccinated with ChAdOx1 nCoV-19. 
Data for these participants have not been included in 
these analyses.
Of 1110 participants from the COV001 and COV002 
studies who had received a single dose of vaccine, 
480 were included in the single-dose immunogenicity 
assessment of antibodies and 44 were included in 
the immunogenicity assessment of T-cell responses 
(appendix 3 p 2). 66 participants from the single-dose 
cohort of COV001 were also offered a second dose, of 
whom 44 were ChAdOx1 nCoV-19 recipients and 22 were 
control group participants who had received MenACWY. 
32 (73%) of 44 participants who had previously received 
a single dose of ChAdOx1 nCoV-19 received their second 
dose, with an interval of 44–45 weeks. Two of these 
participants were subsequently excluded from reacto-
genicity and immunogenicity analyses because they had 
positive PCR tests for SARS-CoV-2 infection within the 
follow-up period, leaving 30 participants for inclusion in 
the two-dose cohort analyses.
The two-dose cohort comprised 321 par ticipants from 
COV001 and COV002 with prime-boost intervals of 
8–12 weeks (267 [83%] of 321), 15–25 weeks (24 [7%]), or 
44–45 weeks (30 [9%]) who had reactogenicity data 
available and were included in our analyses, and 
261 who had immunogenicity data available (115 [44%] 
of 261 had an 8–12 week interval, 116 [44%] had a 
15–25 week interval, and 30 [11%] had a 44–45 week 
interval; appendix 3 p 3).
Baseline characteristics for the one-dose, two-dose, 
and three-dose cohorts are shown in appendix 3 (pp 4–5). 
More than 90% of participants were White. There were 
small differences in the median age of reactogenicity 
cohorts and immunogenicity cohorts. The median 
age of participants in the two-dose cohort antibody 
immunogenicity cohort with an 8–12 week interval 
between the first and second dose was 39 years 
(IQR 30–49), in the 15–25 weeks interval group was 
36 years (30–43), and in the 44–45 weeks interval group 
was 32 years (25–44). In the three-dose cohort, the 
median age of participants in the reactogenicity cohort 
was 37 years (IQR 31–42), in the immunogenicity 
antibody cohort was 37 years (31–42), and in the 
immunogenicity T-cell response cohort 40 years (32–44).
The severity of local and systemic solicited adverse 
reactions 7 days after a second dose were mostly mild to 
moderate irrespective of the interval between doses. Local 
symptoms occurred after a second dose in 201 (75%) of 
267 participants in the 8–12 week interval group, 15 (63%) 
of 24 participants in the 15–25 week interval group, and 
23 (77%) of 30 participants in the 44–45 wee interval 
group (figure 2A; appendix 3 pp 6–9). Systemic reactions 
occurred in 190 (71%) of 267 participants in the 8–12 week 
interval group, 18 (75%) of 24 participants in the 
15–25 week interval group, and 26 (87%) of 30 participants 
in the 44–45 week interval group (figure 2A; appendix 3 
pp 6–9). 65 (81%) of 80 participants in the three-dose 
group reported at least one local symptom after a third 
dose (figure 2B; appendix 3 pp 10–14).
Second dose vaccinations in the two-dose cohort 
were less reactogenic than first dose vaccinations; with 
72 (22%) of 321 participants reporting more than 
two moderate-to-severe systemic symptoms after first 
Figure 5: Antibody responses in participants who received a third dose of ChAdOx1 nCoV-19
(A) Antibody levels to SARS-CoV-2 Victoria/01/2020 spike protein measured by total IgG ELISA (n=75). Datapoints 
in lighter colours represent individual participants and darker datapoints show median values with error bars 
showing the IQRs and with solid lines connecting these median values. (B) Neutralisation titres from a randomly 
selected subset of participants (45 of 75 participants who received a third dose of vaccine and who had an interval 
of 8–16 weeks between their first and second dose). Datapoints represent individual participants for the three 
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vaccination compared with 21 (7%) of 321 participants 
after second vaccinations (appendix 3 pp 6–9). Third dose 
vac cinations were also less reactogenic than first doses, 
with four (5%) of 80 participants in the three-dose cohort 
reporting more than two moderate-to-severe systemic 
symptoms after a third dose compared with 27 (34%) of 
80 participants after the first dose (appendix 3 pp 10–14).
Antibody responses after a single dose of vaccine and 
measured approximately 320 days after vaccination 
remained higher than responses measured at baseline 
(GMTs of 66·00 ELISA units [EUs; 95% CI 47·83–91·08 
vs 1·75 EUs [1·60–1·93]). At day 180, geometric mean 
antibody levels were half the levels observed at the day 28 
peak (GMR 0·51 [95% CI 0·45–0·57]), and by day 320 
were less than a third of the levels at the peak (GMR 0·27 
[0·22–0·34; figure 3A; appendix 3 p 15).
Vaccine-induced cellular immune responses after a 
single dose of ChAdOx1 nCoV-19 followed a similar pattern 
of decay as antibody responses. T-cell responses decreased 
over the course of 6 months but were maintained above 
baseline levels, and at day 180 geometric mean T-cell levels 
were half the levels observed at the day 28 peak (GMR 0·50 
[95% CI 0·41–0·60]; figure 3B; appendix 3 p 15).
Antibody levels 28 days after a second dose of vaccine 
were higher among those with longer intervals between 
doses than among those with shorter intervals between 
doses (median total IgG titre of 923 EUs [IQR 525–1764] 
for 8–12 week interval; 1860 EUs [917–4934] with 
15–25 week interval; and 3738 EUs [1824–6625] with 
44–45 week interval; Kruskal-Wallis test p<0·0001; figure 4; 
appendix 3 p 16). Age was not statistically significant in 
adjusted models (appendix 3 p 16).
6 months after the second dose of vaccine, antibody 
levels remained significantly higher in the group with a 
15–25 week interval between doses compared with an 
8–12 week interval (median 1240 EUs [IQR 432–2002] vs 
278 EUs [166–499]; Wilcoxon rank sum test with con-
tinuity correction p<0·0001; figure 4; appendix 3 p 16).
IgG binding titres to all four variants tested (D614G, 
alpha, beta, and gamma) were significantly greater after 
second dose than after the first dose (p<0·0001 for all 
comparisons [pairwise comparisons using Wilcoxon sign 
rank test]; appendix 3 pp 17, 19).
Antibody responses after a third dose of vaccine were 
assessed in 75 participants who had received their first 
two doses with an interval of 8–16 weeks, and who 
subsequently received their third dose 28–38 weeks after 
the second (median 30 weeks [IQR 30–30]). Administering 
a third dose of vaccine boosted antibody response to 
Victoria/01/2020 SARS-CoV-2 spike protein (figure 5A; 
appendix 3 p 18). Antibody levels after the third dose were 
significantly higher than after the second dose (median 
total IgG titre was 1792 EUs [IQR 899–4634] at 28 days 
after the second dose vs 3746 EUs [2047–6420] 28 days after 
the third dose; pairwise comparison in 73 participants due 
to two samples not being available at these timepoints 
using Wilcoxon signed rank test p=0·0043). Binding 
antibody titres to the beta variant increased after a third 
dose (appendix 3 p 19). Neutralising antibody titres after a 
third dose were higher than those after the second dose 
against alpha (p=0·0023), beta (p<0·0001), and delta 
(p<0·0001) variants (Wilcoxon signed rank test; figure 5B; 
appendix 3 p 20).
Spike-specific cellular immune responses were 
measured after a third dose of ChAdOx1 nCoV-19 in 
15 individuals. These individuals had received their first 
two doses with an interval of 8 weeks, and subsequently 
received their third dose 37–38 weeks after the second 
(median 38 weeks [IQR 38–38]). Median response 
increased from 200 spot-forming units (SFUs) per 
million PBMCs (IQR 127–389) immediately before the 
third dose to 264 SFUs per million PBMCs (131–452) 
14 days after the third dose (p=0·57), and to 399 SFUs per 
million PBMCs (314–662) by 28 days after the third dose 
(p=0·012; figure 6; appendix 3 p 20). Peak responses at 
day 28 after the third dose were not significantly different 
to the responses after the second dose (p=0·060; 
appendix 3 p 20).
Discussion
Antibody levels induced by a single dose of ChAdOx1 
nCoV-19 decreased gradually but remained above baseline 
levels after 1 year. We have previously shown that 
administration of a second dose of vaccine induces higher 
antibody responses by 1 month after the second dose than 
before the second dose, with higher responses with a dose 
interval up to 3 months between the first two doses.3 Here, 
we found that a long extension of the dose interval (up to 
45 weeks) between the first and second dose further 
Figure 6: IFN-γ ELISpot responses in participants who received a third dose of ChAdOx1 nCoV-19
15 participants with an interval of 8 weeks between their first and second doses were assessed for ELISpot 
responses. These participants received their third dose 37–38 weeks after the second dose (median 38 weeks 
[IQR 38–38]). Datapoints in lighter colours represent individual participants and darker datapoints show median 
values with error bars showing the IQRs and with solid lines connecting these median values. The dotted horizontal 
line represents the lower limit of detection of the assay (48 SFU per million PBMCs). SFU=spot-forming unit. 
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enhances the immune response to the second dose when 
compared with shorter dose intervals. Furthermore, for 
the first time, we showed that a third dose of ChAdOx1 
nCoV-19 can induce a strong boost to immune responses 
to the transgene product, SARS-CoV-2 spike protein, and 
that these responses result in increased neutralising 
antibody titres and enhanced antibody activity against 
variants.
The devastating impact of COVID-19 is most apparent 
in countries with low vaccine coverage and little health-
care infrastructure, including low-income and middle-
income countries. Global vaccine shortages and policy 
decisions implemented at national levels have curtailed 
vaccine supplies for some countries where substantial 
numbers of individuals have already received one dose of 
vaccine. We have previously shown that protection against 
symptomatic COVID-19 is maintained after a single dose 
of ChAdOx1 nCoV-19 for at least 3 months, despite some 
waning of antibody levels3 and we now report that the 
antibody levels remain above baseline for at least 1 year 
after single dose immunisation. These data are important 
for those countries where administration of a second dose 
is delayed because of a shortage of supply. We also showed 
here that an extended interval between the first and 
second dose of ChAdOx1 nCoV-19 results in a significantly 
higher antibody response 28 days after the second dose 
than with shorter intervals. This finding is consistent with 
previous data showing a longer interval between first and 
second dose of ChAdOx1 nCoV-19 resulted in an increase 
in antibody titres,3 thus providing further reassurance that 
a delay in admin istration of the second dose will not 
compromise the level of protection attained. Similar 
findings have been reported with other vaccines;1,7,8 a 
delayed two-dose regimen against HPV, given at least 
6 months apart, results in as good or better antibody 
response than does three doses. A second dose of 
ChAdOx1 nCoV-19 is well tolerated in a delayed two-dose 
schedule and a third dose is also well tolerated. Reports 
have emerged of thrombosis and thrombocytopenia after 
the first dose of ChAdOx1 nCoV-19,9 and information from 
Public Health England indicates that this very rare event 
might not occur after a second dose.10
If booster vaccinations against SARS-CoV-2 will be 
required, perhaps to counter waning immunity or to 
augment protection against emerging variants, is not yet 
known. Here, we show that a third dose of ChAdOx1 
nCoV-19 is well tolerated and significantly boosts antibody 
titres above those measured after the second dose to the 
level associated with 80% vaccine efficacy, or higher, after 
two vaccine doses (unpublished; preprint data available11). 
Higher titre neutralising antibodies against alpha, beta, 
and delta variants of SARS-CoV-2 were induced 28 days 
after a third dose vaccination than after the second dose. 
Spike-specific T-cell responses were boosted after a third 
dose of ChAdOx1 nCoV-19 and were similar in magnitude 
to the responses measured after two doses. Although pre-
existing immunity to human adenoviral vectors has been 
shown to dampen vaccine-induced immune responses,12,13 
here we found no evidence that repeated use of a 
replication-deficient simian adenoviral vector induces 
antivector immunity at a level sufficient to impair 
responses to further vaccination. The third dose was well 
tolerated by participants with lower reactogenicity than 
after the first dose.
Our study has several limitations, including a paucity 
of T-cell data after a late second dose, a paucity of 
tolerability data after the second dose for those who were 
recruited to receive a third dose, and the small number of 
participants who were available at 1 year after single dose 
who still had only received one dose (mainly due to 
being offered a second dose after unblinding, as per 
protocol). Thus far, data are only available 28 days after 
the third dose; however, follow-up at 6 months is planned. 
Participants were aged 18–55 years and caution should be 
taken when extrapolating our findings to beyond this age 
range. The sample size in this study is not sufficiently 
large to assess rare vaccine side-effects, but there were no 
tolerability concerns reported in those receiving a late 
second dose or a third dose booster. These results are 
from a mainly White population and cannot necessarily 
be generalised to other populations.
Here, we found that immunity induced by the viral 
vectored vaccine ChAdOx1 nCoV-19 is maintained for 
long periods after a first dose, with greater boosting of 
effects after the second dose after a longer interval 
between doses than shorter intervals. Therefore, a single 
dose of ChAdOx1 nCoV-19 with a second dose given after 
an extended period might be an effective strategy3,14 in 
settings where vaccine supplies are scarce in the short 
term. A third dose resulted in a further increase in 
immune responses, including increased neutralisation 
of variant SARS-CoV-2 viruses, and could be used to 
increase vaccine efficacy against variants in susceptible 
populations.
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